Compare Incyte Corporation (INCY) vs TotalEnergies SE (TTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs TotalEnergies SE — how do they compare? Incyte Corporation trades at $118 (market cap $23.11B), while TotalEnergies SE trades at $83.44 (market cap $179.99B). The key difference: TotalEnergies SE is far larger — about 7.8× Incyte Corporation's market cap, and TotalEnergies SE pays a 5.22% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | TTE | |
|---|---|---|
Market Cap | $23.11B | $179.99B |
Sector | Health | Energy |
52-Week High | $118.52 | $93.60 |
52-Week Low | $67.38 | $57.39 |
Enterprise Value | $19.13B | $214.14B |
Dividend Yield | — | 5.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
TotalEnergies (TTE) trades at $81.23, down 0.2% on the day, with a bullish technical signal supported by moving averages. The company reported a Q1 2026 EPS beat of $2.45 versus $2.22 expected, though revenue has declined from $263.3B in 2022 to $182.3B in 2025. Valuation remains attractive with a P/E of 12.08 and P/S of 0.97. Recent news highlights strategic divestments in solar and new LNG shipments to Asia, reflecting a focus on profitable growth areas.
The outlook is positive with a consensus price target of $100, implying 23% upside, supported by 57.6% analyst buy ratings. Risks include ongoing revenue pressure, geopolitical exposure in the Middle East, and regulatory climate mandates. Cash flow stability and shareholder returns via dividends provide a cushion, but execution on production growth and cost management is critical for sustained appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →
